AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23747051 — intervention group
Group type: COMPARATOR
Intervention: docetaxel+oxaliplatin+cetuximab (DOCOX+C)
Number of subjects: 150
Study 20371564 — intervention group
Group type: EXPERIMENTAL
Intervention: 8‐week exercise training programme to correct posture
Number of subjects: 28
Study 18655557 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA)
Number of subjects: 66
Study 18655557 — intervention group
Group type: COMPARATOR
Intervention: Control group (rehabilitation training + acupoint percutaneous electric stimulation)
Number of subjects: 66
Study 18655557 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint token puncturing (TP)
Number of subjects: 66
Study 15985339 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patches with counselling
Number of subjects: 20
Study 15985339 — intervention group
Group type: COMPARATOR
Intervention: Counselling only (Control)
Number of subjects: 20
Study 12640194 — intervention group
Group type: EXPERIMENTAL
Intervention: SQV hard-gelatin capsule (HGC)/ritonavir (RTV), 1600/100 mg
Number of subjects: 13
Study 12640194 — intervention group
Group type: COMPARATOR
Intervention: SQV soft-gelatin capsule (SGC)/ritonavir (RTV), 1600/100 mg
Number of subjects: 13
Study 12640194 — intervention group
Group type: COMPARATOR
Intervention: SQV soft-gelatin capsules (SGCs)
Number of subjects: 13
Study 12640194 — intervention group
Group type: EXPERIMENTAL
Intervention: SQV hard-gelatin capsules (HGCs)
Number of subjects: 13
Study 10759911 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan, 2.5 mg
Number of subjects: 1445
Study 10759911 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan, 5 mg
Number of subjects: 1445
Study 10759911 — intervention group
Group type: COMPARATOR
Intervention: Sumatriptan, 25 mg
Number of subjects: 1445
Study 10759911 — intervention group
Group type: COMPARATOR
Intervention: Sumatriptan, 50 mg
Number of subjects: 1445
Study 8698547 — intervention group
Group type: EXPERIMENTAL
Intervention: Preconceptional multivitamin supplementation
Number of subjects: 0
Study 8698547 — intervention group
Group type: COMPARATOR
Intervention: Placebo-like trace element supplementation
Number of subjects: 0
Study 1299486 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity exercise
Number of subjects: 16
Study 1299486 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity exercise
Number of subjects: 16
Study 1299486 — intervention group
Group type: COMPARATOR
Intervention: Both exercise intensities
Number of subjects: 16
Study 1299486 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity exercise following a meal
Number of subjects: 16
Study 1299486 — intervention group
Group type: COMPARATOR
Intervention: Low intensity exercise following a meal
Number of subjects: 16
Study 6240537 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold
Number of subjects: 50
Study 6240537 — intervention group
Group type: COMPARATOR
Intervention: D-penicillamine
Number of subjects: 50
Study 6240537 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term follow-up
Number of subjects: 50
Study 6240537 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold or D-penicillamine in remission
Number of subjects: 50
Study 6240537 — intervention group
Group type: EXPERIMENTAL
Intervention: D-penicillamine toxicity
Number of subjects: 50
Study 31364269 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg/day)
Number of subjects: 0
Study 31364269 — intervention group
Group type: COMPARATOR
Intervention: Saxagliptin (5 mg/day)
Number of subjects: 0
Study 28202270 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% glucose solution
Number of subjects: 18
Study 28202270 — intervention group
Group type: COMPARATOR
Intervention: Fructose solution
Number of subjects: 18
Study 26476459 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide + varenicline
Number of subjects: 74
Study 26476459 — intervention group
Group type: COMPARATOR
Intervention: Placebo + varenicline
Number of subjects: 74
Study 25305000 — intervention group
Group type: EXPERIMENTAL
Intervention: M72/AS01 (1 or 2 doses)
Number of subjects: 300
Study 25305000 — intervention group
Group type: COMPARATOR
Intervention: Meningitis vaccine or EPI vaccines alone
Number of subjects: 300
Study 25305000 — intervention group
Group type: EXPERIMENTAL
Intervention: M72/AS01
Number of subjects: 300
Study 21093072 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 13608
Study 19602614 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal Dialysis (PD)
Number of subjects: 287
Study 19602614 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 287
Study 19602614 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls (C)
Number of subjects: 287
Study 17643582 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 15904
Study 17643582 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 15904
Study 17643582 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 15904
Study 17643582 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 15904
Study 17643582 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 15904
Study 17643582 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality
Number of subjects: 15904
Study 15863409 — intervention group
Group type: EXPERIMENTAL
Intervention: MMSE cut-off of 23/24
Number of subjects: 15051
Study 15863409 — intervention group
Group type: EXPERIMENTAL
Intervention: MMSE cut-off of 17/18
Number of subjects: 15051
Study 15863409 — intervention group
Group type: EXPERIMENTAL
Intervention: MMSE 23/24
Number of subjects: 15051
Study 15863409 — intervention group
Group type: EXPERIMENTAL
Intervention: Living alone
Number of subjects: 15051
Study 12043780 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral TKR
Number of subjects: 227
Study 12043780 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral TKR
Number of subjects: 227
Study 12043780 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented replacement
Number of subjects: 227
Study 12043780 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementless replacement
Number of subjects: 227
Study 12043780 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up venograms at six months
Number of subjects: 227
Study 12043780 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary embolism assessment
Number of subjects: 227
Study 10446831 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 21
Study 10446831 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl and midazolam
Number of subjects: 21
Study 7597610 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 38
Study 7597610 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 38
Study 1866817 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloramphenicol ointment and an eye patch for six hours followed by chloramphenicol eyedrops six times a day for six days.
Number of subjects: 40
Study 1866817 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol ointment and double eye patches for twenty-four hours as the only treatment.
Number of subjects: 40
Study 6810423 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised sodium cromoglycate
Number of subjects: 44
Study 6810423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 6810423 — intervention group
Group type: COMPARATOR
Intervention: Both age groups (sodium cromoglycate and placebo)
Number of subjects: 44
Study 6810423 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate
Number of subjects: 44
Study 6810423 — intervention group
Group type: COMPARATOR
Intervention: Nebulised water (placebo response)
Number of subjects: 44
Study 31058947 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted quality improvement intervention including case management, reminders, a roadmap and checklist for the therapeutic plan, educational materials, and periodic audit and feedback reports.
Number of subjects: 1624
Study 31058947 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 1624
Study 31058947 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted quality improvement intervention
Number of subjects: 1624
Study 29934526 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0
Study 29934526 — intervention group
Group type: COMPARATOR
Intervention: No beta-blockers
Number of subjects: 0
Study 27111192 — intervention group
Group type: EXPERIMENTAL
Intervention: TC‐3 gel + 200 U OnabotA (Group B)
Number of subjects: 39
Study 27111192 — intervention group
Group type: COMPARATOR
Intervention: DMSO (Group D)
Number of subjects: 39
Study 27111192 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl (placebo, Group A)
Number of subjects: 39
Study 27111192 — intervention group
Group type: COMPARATOR
Intervention: TC‐3 gel + 200 U OnabotA + DMSO (Group C)
Number of subjects: 39
Study 25092553 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Postural Reeducation (GPR)
Number of subjects: 30
Study 25092553 — intervention group
Group type: COMPARATOR
Intervention: Segmental Exercises (SE)
Number of subjects: 30
Study 22176488 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest breaks according to perceived decrements in postural stability
Number of subjects: 16
Study 22176488 — intervention group
Group type: EXPERIMENTAL
Intervention: Static pure tone auditory stimulation
Number of subjects: 16
Study 22176488 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving conversation auditory stimulation
Number of subjects: 16
Study 22176488 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 16
Study 20857370 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine disinfection of floors after every surgical procedure
Number of subjects: 0
Study 20857370 — intervention group
Group type: COMPARATOR
Intervention: Disinfection of floors only in case of visible contamination
Number of subjects: 0
Study 20857370 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (routine disinfection and disinfection after visible contamination)
Number of subjects: 0
Study 17990225 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifurtimox-eflornithine combination therapy (eflornithine 400 mg/kg per day IV every 12 h for 7 days + nifurtimox 15 mg/kg per day orally every 8 h for 10 days)
Number of subjects: 103
Study 17990225 — intervention group
Group type: COMPARATOR
Intervention: Eflornithine alone (400 mg/kg per day IV every 6 h for 14 days)
Number of subjects: 103
Study 15022037 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D‐LSGA based measurements in treated group
Number of subjects: 30
Study 15022037 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 30
Study 12926186 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific immunotherapy (SIT) with Olea europaea extract, administered preseasonally with a maintenance dose 3.8 times higher than conventional treatments, reaching a maximal dose of 75 BU (45 micrograms Ole e 1).
Number of subjects: 0
Study 12926186 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SIT treatment).
Number of subjects: 0
Study 9609132 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/day Carbimazole for 12 months (Group 1, n = 23)
Number of subjects: 57
Study 9609132 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 mg/day for the first month, 30 mg/day for the second, and 20 mg/day for the remaining 10 months of Carbimazole (Group 2, n = 34)
Number of subjects: 57
Study 9609132 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 30)
Number of subjects: 57
Study 9815961 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposome‐encapsulated muramyl tripeptide phosphatidylethanolamine (L‐MTP‐PE), 2 mg/m2 i.v. twice weekly for 8 weeks
Number of subjects: 104
Study 9815961 — intervention group
Group type: COMPARATOR
Intervention: Placebo liposomes (lipid equivalent), twice weekly for 8 weeks
Number of subjects: 104
Study 9815961 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposome‐encapsulated muramyl tripeptide phosphatidylethanolamine (L‐MTP‐PE), 2 mg/m2 i.v. once or twice weekly for 8 weeks
Number of subjects: 104
Study 9815961 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin chemotherapy (CDDP), 70 mg/m2 i.v. every 21 days x 4
Number of subjects: 104
Study 2677863 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritodrine hydrochloride
Number of subjects: 106
Study 2677863 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 106
Study 375153 — intervention group
Group type: EXPERIMENTAL
Intervention: promethazine‐A.P.C. combination
Number of subjects: 149
Study 31723049 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy (MT) procedures performed
Number of subjects: 166
Study 31723049 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean MT direct time burden during each 24-hour call
Number of subjects: 166
Study 31723049 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of consultations for thrombectomy based on time of day
Number of subjects: 166
Study 31723049 — intervention group
Group type: EXPERIMENTAL
Intervention: MT procedural volumes
Number of subjects: 166
Study 31050167 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS targeting the left DLPFC (10 Hz, 2000 pulses over 20 minutes, 8 sessions over 4 weeks)
Number of subjects: 45
Study 31050167 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 45
Study 31050167 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS targeting the left DLPFC
Number of subjects: 45
Study 28779937 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga Training Program (YTP) - 8 weeks, 24 sessions
Number of subjects: 29
Study 26189560 — intervention group
Group type: EXPERIMENTAL
Intervention: GEMOX plus erlotinib
Number of subjects: 103
Study 26189560 — intervention group
Group type: COMPARATOR
Intervention: GEMOX
Number of subjects: 103
Study 26189560 — intervention group
Group type: EXPERIMENTAL
Intervention: GEMOX with or without erlotinib
Number of subjects: 103
Study 23659338 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 supplementation (500 mg/day)
Number of subjects: 45
Study 23659338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 21805296 — intervention group
Group type: EXPERIMENTAL
Intervention: Yiqi Bufei Recipe (YBR)
Number of subjects: 60
Study 21805296 — intervention group
Group type: COMPARATOR
Intervention: Control group with normal lung function
Number of subjects: 60
Study 21805296 — intervention group
Group type: COMPARATOR
Intervention: Positive control group (PI without treatment)
Number of subjects: 60
Study 19136216 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone levels
Number of subjects: 21
Study 17223420 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention plus intensive, guideline-driven medical therapy
Number of subjects: 2287
Study 17223420 — intervention group
Group type: COMPARATOR
Intervention: Intensive medical therapy alone
Number of subjects: 2287
Study 15378098 — intervention group
Group type: EXPERIMENTAL
Intervention: Seated exercise program (three times per week for four cycles of chemotherapy)
Number of subjects: 38
Study 15378098 — intervention group
Group type: EXPERIMENTAL
Intervention: Seated exercise program
Number of subjects: 38
Study 15378098 — intervention group
Group type: COMPARATOR
Intervention: Control group (no seated exercise)
Number of subjects: 38
Study 11469436 — intervention group
Group type: EXPERIMENTAL
Intervention: P2 of 2 msec
Number of subjects: 62
Study 11469436 — intervention group
Group type: COMPARATOR
Intervention: P2 of 5 msec
Number of subjects: 62
Study 11469436 — intervention group
Group type: EXPERIMENTAL
Intervention: P2 of 2 msec with amiodarone
Number of subjects: 62
Study 11469436 — intervention group
Group type: EXPERIMENTAL
Intervention: P2 of 2 msec with d,l-sotalol
Number of subjects: 62
Study 10451971 — intervention group
Group type: EXPERIMENTAL
Intervention: Foldable intraocular lens (IOL) implantation after phacoemulsification
Number of subjects: 49
Study 7616557 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (Dormicum) 7.5 mg
Number of subjects: 98
Study 7616557 — intervention group
Group type: COMPARATOR
Intervention: Promethazine (Phenergan) 25 mg
Number of subjects: 98
Study 7616557 — intervention group
Group type: COMPARATOR
Intervention: Droperidol 2.5 mg
Number of subjects: 98
Study 7616557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 3283661 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 1000 mg
Number of subjects: 12
Study 3283661 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 1500 mg
Number of subjects: 12
Study 3283661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29371075 — intervention group
Group type: EXPERIMENTAL
Intervention: COLD water (0.4±0.4°C)
Number of subjects: 12
Study 29371075 — intervention group
Group type: EXPERIMENTAL
Intervention: COOL water (7.3±0.8°C)
Number of subjects: 12
Study 29371075 — intervention group
Group type: COMPARATOR
Intervention: TEMP water (22.1±1.2°C)
Number of subjects: 12
Study 27078022 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib plus Paclitaxel
Number of subjects: 479
Study 27078022 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab plus Paclitaxel
Number of subjects: 479
Study 25587825 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilisation to the toilet (Group I)
Number of subjects: 152
Study 25587825 — intervention group
Group type: COMPARATOR
Intervention: Use of a bedpan or urinal in the bed (Group C)
Number of subjects: 152
Study 23660628 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide-dexamethasone (TD)
Number of subjects: 112
Study 23660628 — intervention group
Group type: COMPARATOR
Intervention: Non-CR-predicted patients
Number of subjects: 112
Study 20937993 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtered air
Number of subjects: 126
Study 20937993 — intervention group
Group type: COMPARATOR
Intervention: Perfluoropropane gas
Number of subjects: 126
Study 18070831 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of temocillin (4 g/day)
Number of subjects: 12
Study 18070831 — intervention group
Group type: COMPARATOR
Intervention: Twice daily administration of temocillin (2 g every 12 h)
Number of subjects: 12
Study 16571276 — intervention group
Group type: EXPERIMENTAL
Intervention: ZY‐4
Number of subjects: 72
Study 16571276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 12711383 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol‐ and fluoride‐containing dentifrice (XF)
Number of subjects: 6
Study 12711383 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐xylitol‐ and fluoride‐containing dentifrice (F)
Number of subjects: 6
Study 12711383 — intervention group
Group type: COMPARATOR
Intervention: Non‐xylitol‐ and non‐fluoride‐containing dentifrice (NonX‐NonF)
Number of subjects: 6
Study 15101878 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based pharmaceutical care program
Number of subjects: 107
Study 15101878 — intervention group
Group type: COMPARATOR
Intervention: Routine pharmaceutical care (control)
Number of subjects: 107
Study 9365750 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia textbook (MMTB)
Number of subjects: 89
Study 9365750 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional lecture
Number of subjects: 89
Study 9365750 — intervention group
Group type: EXPERIMENTAL
Intervention: Printed textbook
Number of subjects: 89
Study 9365750 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 89
Study 1559428 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual withdrawal
Number of subjects: 110
Study 1559428 — intervention group
Group type: COMPARATOR
Intervention: Sudden withdrawal
Number of subjects: 110
Study 1559428 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 110
Study 3936089 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-abstinence smoking motivation (dependent smoking subscale)
Number of subjects: 29
Study 3936089 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-abstinence smoking motivation (indulgent smoking subscale)
Number of subjects: 29
Study 3936089 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-abstinence plasma nicotine concentration
Number of subjects: 29
Study 3936089 — intervention group
Group type: EXPERIMENTAL
Intervention: Expired-air CO
Number of subjects: 29
Study 3936089 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual daily cigarette consumption
Number of subjects: 29
Study 31829276 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acuTENS treatment for 45 min once a day for five consecutive days
Number of subjects: 60
Study 31829276 — intervention group
Group type: COMPARATOR
Intervention: Sham acuTENS treatment for 45 min once a day for five consecutive days
Number of subjects: 60
Study 31829276 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acuTENS treatment
Number of subjects: 60
Study 31829276 — intervention group
Group type: COMPARATOR
Intervention: Sham acuTENS treatment
Number of subjects: 60
Study 30342553 — intervention group
Group type: EXPERIMENTAL
Intervention: ATG
Number of subjects: 525
Study 30342553 — intervention group
Group type: COMPARATOR
Intervention: CD34+
Number of subjects: 525
Study 30342553 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse cytogenetic
Number of subjects: 525
Study 30342553 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrelated donor
Number of subjects: 525
Study 30342553 — intervention group
Group type: COMPARATOR
Intervention: ATG vs CD34+
Number of subjects: 525
Study 26716896 — intervention group
Group type: EXPERIMENTAL
Intervention: ADV‐TK
Number of subjects: 53
Study 26716896 — intervention group
Group type: EXPERIMENTAL
Intervention: ADV‐TK (subgroup of glioblastoma)
Number of subjects: 53
Study 26716896 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 53
Study 24815889 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 19
Study 24815889 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 27.5 μg
Number of subjects: 19
Study 24815889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 22688444 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.2 mg/kg
Number of subjects: 120